tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Contract Research Organization'

Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment without Competition

Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment without Competition

Written by ι Stock Market Media Group — April 22, 2014

When Nuvilex, Inc. (OTCQB: NVLX) named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in advanced pancreatic cancer, the company also stated it will apply for “Orphan Drug” status.  This is a designation that will allow Nuvilex to exclusively market its pancreatic cancer treatment using the Cell-in-a-Box® technology combined with the anticancer drug ifosfamide.

Treatments for pancreatic cancer engender an Orphan Drug designation in most ...

Read More →
0

Nuvilex Investors Should Read Between the Lines as Company Attracts World Renowned Oncologist

Written by ι Stock Market Media Group Staff — April 3, 2014

NEW YORK, NY–(Apr 3, 2014) – That loud noise you hear coming from Nuvilex, Inc. (OTCQB: NVLX) this week is the collective excitement of many investors after the company stated it would be working with Translational Drug Development or TD2 and Dr. Daniel Von Hoff, the world’s leading figure in pancreatic cancer, to develop its pancreatic cancer and other treatments utilizing Cell-in-a-Box® technology. Quite honestly Nuvilex may have just announced what ...

Read More →
0

Nuvilex, Inc. Lands Dr. Daniel Von Hoff to Lead Clinical Trials and TD2 as Contract Research Organization (CRO)

Written by ι Stock Market Media Group Staff — April 1, 2014

World Renowned Dr. Daniel Von Hoff to Lead Nuvilex’s Clinical Trials

Nuvilex Signs TD2 as Contract Research Organization (CRO)

  • Oncology Pioneer Dr. Daniel Von Hoff Agrees to Lead Nuvilex’s Pancreatic Cancer Clinical Trials
  • Dr. Von Hoff Developed Eli Lilly’s Gemzar®
  • Dr. Von Hoff Developed  Celgene’s Abraxane® 
  • Dr. Von Hoff is the World’s Leading Authority on Pancreatic Cancer & Now He will Lead Nuvilex’s Clinical Trials
  • Nuvilex Also Retains TD2 – The Precision Oncology CRO™ for Clinical Trials

The News Released This Morning by NVLX is Industry Changing and it will surely reverberate ...

Read More →
0
ContactUs.com